Bebe Bottoms Spray
NDC Package 51672-5318-3
Package Information
Bebe Bottoms (zinc oxide) sprays is a medication used to treat and prevent diaper rash and other minor skin irritations (e.g., burns, cuts, scrapes). This formulation utilizes a spray delivery system. Marketed by Taro Pharmaceuticals U.s.a., Inc., this product is identified by NDC 51672-5318 and is authorized under FDA application M016.
Identification & Billing
- RxCUI: 1232104 - zinc oxide 10 % Topical Spray
- RxCUI: 1232104 - zinc oxide 100 MG/ML Topical Spray
- RxCUI: 1232104 - ZNO 100 MG/ML Topical Spray
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 51672 - Taro Pharmaceuticals U.s.a., Inc.
- 51672-5318 - Bebe Bottoms
- 51672-5318-3 - 1 BOTTLE, SPRAY in 1 CARTON / 50 mL in 1 BOTTLE, SPRAY
- 51672-5318 - Bebe Bottoms
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (51672-5318). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 51672-5318-3 identifies a specific commercial package of 1 bottle, spray in 1 carton / 50 ml in 1 bottle, spray of Bebe Bottoms, a human over the counter drug labeled by Taro Pharmaceuticals U.s.a., Inc.. This spray is formulated for topical use and contains zinc oxide as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Taro Pharmaceuticals U.s.a., Inc. on December 01, 2023. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
This medication is used to treat and prevent diaper rash and other minor skin irritations (e.g., burns, cuts, scrapes). It works by forming a barrier on the skin to protect it from irritants/moisture.
How is this Taro Pharmaceuticals U.s.a., Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 51672531803. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.